Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Troy A. Bemis, James J. La Clair, Michael D. Burkart
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8042-8052
Closed Access | Times Cited: 151

Showing 1-25 of 151 citing articles:

Protein degraders enter the clinic — a new approach to cancer therapy
Deborah Chirnomas, Keith R. Hornberger, Craig M. Crews
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 265-278
Closed Access | Times Cited: 332
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Guoqiang Dong, Yu Ding, Shipeng He, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10606-10620
Closed Access | Times Cited: 223
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 153
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
Charles E. Hendrick, Jeff R. Jorgensen, Charu Chaudhry, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 7, pp. 1182-1190
Open Access | Times Cited: 96
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 92
Accelerated rational PROTAC design via deep learning and molecular simulations
Shuangjia Zheng, Youhai Tan, Zhenyu Wang, et al.
Nature Machine Intelligence (2022) Vol. 4, Iss. 9, pp. 739-748
Closed Access | Times Cited: 78
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 73
Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation
Ryan P. Wurz, Huan Rui, Ken Dellamaggiore, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 51
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 50
Link-INVENT: generative linker design with reinforcement learning
Jeff Guo, Franziska Knuth, Christian Margreitter, et al.
Digital Discovery (2023) Vol. 2, Iss. 2, pp. 392-408
Open Access | Times Cited: 46
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 46
Recent Advances in Covalent Drug Discovery
D. M. Schaefer, Xinlai Cheng
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 663-663
Open Access | Times Cited: 43
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
PROTAC technology: From drug development to probe technology for target deconvolution
Si Yan, Guangshuai Zhang, Wei Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116725-116725
Closed Access | Times Cited: 19
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 3
Targeted Protein Acetylation in Cells Using Heterobifunctional Molecules
Wei Wang, Liyun Chen, Jacob M. Wozniak, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 40, pp. 16700-16708
Open Access | Times Cited: 65
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Nicolas Guedeney, Marie Cornu, Florian Schwalen, et al.
Drug Discovery Today (2022) Vol. 28, Iss. 1, pp. 103395-103395
Open Access | Times Cited: 65
Recent Advances in PROTACs for Drug Targeted Protein Research
Tingting Yao, Heng Xiao, Hong Wang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10328-10328
Open Access | Times Cited: 43
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 32
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
Qindi He, Xiaofei Zhao, Donglin Wu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115741-115741
Closed Access | Times Cited: 25
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers
Zehui Zhou, Guizhen Zhou, Chuan Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4197-4214
Closed Access | Times Cited: 23
Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 776-785
Closed Access | Times Cited: 23
Degraders upgraded: the rise of PROTACs in hematological malignancies
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top